680 reports of this reaction
1.9% of all ZIPRASIDONE HYDROCHLORIDE reports
#9 most reported adverse reaction
DYSTONIA is the #9 most commonly reported adverse reaction for ZIPRASIDONE HYDROCHLORIDE, manufactured by ROERIG. There are 680 FDA adverse event reports linking ZIPRASIDONE HYDROCHLORIDE to DYSTONIA. This represents approximately 1.9% of all 35,561 adverse event reports for this drug.
Patients taking ZIPRASIDONE HYDROCHLORIDE who experience dystonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSTONIA is a less commonly reported adverse event for ZIPRASIDONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dystonia, the following adverse reactions have been reported for ZIPRASIDONE HYDROCHLORIDE:
The following drugs have also been linked to dystonia in FDA adverse event reports:
DYSTONIA has been reported as an adverse event in 680 FDA reports for ZIPRASIDONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSTONIA accounts for approximately 1.9% of all adverse event reports for ZIPRASIDONE HYDROCHLORIDE, making it a notable side effect.
If you experience dystonia while taking ZIPRASIDONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.